Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (30 mg/ml), DMF (20 mg/ml)
- Melting Point
- 295-296 °C (lit.)
Category: Phytochemicals
Astragaloside IV (AS-IV) is a bioactive saponin and constituent of the traditional chinese medicine plant Astragali radix. AS-IV has multiple pharmacologic effects, including anti-inflammatory, antioxidative, anti-asthma, antidiabetes, anticancer, immunoregulation, neuroprotective and cardioprotective properties via numerous signaling pathways. This includes inhibition of NF-kappaB, inducing hypoxia-inducible factor-1α accumulation via PI3K/Akt pathway, reducing Aβ production in Alzheimer’s disease through inhibition of BACE1, working as a natural PPARγ agonist, improving lipid metabolism in obese mice, enhancing chemosensitivity through B7-H3 inhibition, and suppressing glucose-induced NLRP3 inflammasome activation.
Synonyms | AS-IV, AST-IV, Astrasieversianin XIV, Cyclosieversioside F, Cyclosiversioside F, Astramembrannin I, Astragaloside A |
---|---|
Purity | ≥98% (HPLC) |
Appearance | White to off-white powder |
CAS-Number | 84687-43-4 |
Molecular Formula | C41H68O14 |
Molecular Weight | 784.98 |
Identity | 1H-NMR |
Solvents | DMSO (30 mg/ml), DMF (20 mg/ml) |
Melting Point | 295-296 °C (lit.) |
Smiles | O[C@H]1C[C@@]2(C)[C@]3([H])C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@]5([H])C(C)(C)[C@@H](O[C@H]6OC[C@@H](O)[C@H](O)[C@H]6O)CC[C@]57[C@]3(C7)CC[C@]2(C)[C@H]1[C@]8(C)O[C@H](C(C)(O)C)CC8 |
InChi Key | QMNWISYXSJWHRY-RXMVGYINSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Transportation | Not dangerous goods |
References | (1) Y.P. Wang, et al., Acta Pharmacol. Sin. 23, 263 (2002), (2) W.J. Zhang, et al., Thromb. Haemost. 90, 904 (2003), (3) M.E. Xu, et al., Acta Pharmacol. Sin. 27, 229 (2006), (4) W.S. Chan, et al., Neurochem. Int. 55, 414 (2009), (5) L. Zhang, et al., J. Pharmacol. Exp. Ther. 338, 485 (2011), (6) X. Chen, et al., J. Ethnopharmacol. 139, 721 (2012), (7) D. Gui, et al., PLoS One 7, e39824 (2012), (8) S. Ren, et al., J. Tradit. Chin. Med. 33, 413 (2013) (Review), (9) H. Wu, et al., Sci. Rep. 6, 30190 (2016), (10) C.S. He, et al., Cell Physiol. Biochem. 40, 1221 (2016), (11) X. Wang, et al., Mol. Neurobiol. 54, 2939 (2017), (12) L. Li, et al., Fundam. Clin. Pharmacol. 31, 17 (2017) (Review), (13) L. Xia, et al., Exp. Ther. Med. 14, 5569 (2017), (14) P. Sun, et al., Front. Biosci. 24, 597 (2019), (15) B. Leng, et al., Mediators Inflamm. 2019, 1082497 (2019), (16) Z. Zhang, et al., Mol. Med. Rep. 20, 4612 (2019) |
InChi | InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33+,34+,37+,38-,39+,40-,41+/m0/s1 |
Quantity | 50 mg, 100 mg, Bulk |